Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene International Sàrl, a subsidiary of Celgene Corporation, today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug.

13 Dec 2011

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

A three-drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center.

13 Dec 2011

Celgene announces interim results of REVLIMID study on CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

12 Dec 2011

Onyx announces data from three carfilzomib studies on RRMM

Onyx Pharmaceuticals, Inc. today announced summaries of three poster presentations of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA.

12 Dec 2011

Immunomodulators show promise against multiple myeloma

Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, says the study's senior investigator, Keith Stewart, M.B., Ch.B. of Mayo Clinic in Arizona. Dr. Stewart presented the results at the 53rd annual meeting of the American Society of Hematology in San Diego.

12 Dec 2011

BioInvent announces new BI-505 preclinical data on multiple myeloma

BioInvent International AB announced today that new preclinical data has been presented on its BI-505 programme that demonstrates anti-cancer activity in multiple myeloma and beneficial effect on bone density.

12 Dec 2011

SCRI to present findings of blood cancer trials at 53rd ASH annual meeting

Sarah Cannon Research Institute (SCRI) investigators will present the findings of several important blood cancer trials during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego December 10-13.

12 Dec 2011

Positive dose-escalation/expansion data from Array BioPharma's ARRY-614 Phase 1 MDS study

Array BioPharma Inc. today announced positive dose-escalation/expansion data for its novel, small molecule dual p38/Tie2 inhibitor, ARRY-614.

12 Dec 2011

Onyx receives FDA Standard Review designation for carfilzomib NDA to treat RRMM

Onyx Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Standard Review designation to the New Drug Application (NDA) for carfilzomib for the potential treatment of patients with relapsed and refractory multiple myeloma.

12 Dec 2011

Positive data from Aeterna Zentaris AEZS-131 preclinical study on TNBC

Aeterna Zentaris Inc. today announced positive preclinical data in triple-negative breast cancer (TNBC) for its highly selective Erk 1/2 inhibitor anticancer compound, AEZS-131.

11 Dec 2011

Signal Genetics to launch second generation Myeloma product, MyPRS Plus

Signal Genetics announced today, at the American Society of Hematology Annual Meeting, that the Company is launching its next generation Multiple Myeloma product, MyPRS Plus, effective January 1, 2012.

9 Dec 2011

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed an agreement with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765.

9 Dec 2011

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.

2 Dec 2011

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd., presented Compugen's Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets.

1 Dec 2011

FDA grants IND for AEZS-130 Phase 2A trial in cancer cachexia

Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has granted Jose M. Garcia, MD, PhD, Assistant Professor, Division of Diabetes Endocrinology and Metabolism, Departments of Medicine and Molecular and Cell Biology, Baylor College of Medicine and Michael I. DeBakey Veterans Administration Medical Center, in Houston Texas, an Investigational New Drug approval for the initiation of a Phase 2A trial to assess the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130, in patients with cancer cachexia.

28 Nov 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011

Biochemists identify structure of hydroxyurea that specifically inhibits proteasome

As the "recycling plant" of the cell, the proteasome regulates vitally important functions. When it is inhibited, the cell chokes on its own waste. Cancer cells, in particular, are very sensitive because they need the proteasome for their uncontrolled growth. Biochemists at the Technische Universitaet Muenchen (TUM) have now identified the lead structure of a new class of drugs that attacks the proteasome in an unusual way. New medication could be developed on the basis of this previously unknown binding mechanism.

22 Nov 2011

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.

21 Nov 2011

Chloroquine-chemotherapy combination holds potential for metastatic breast cancer treatment

An anti-malaria drug used for more than 60 years is now being studied for use in breast cancer patients whose disease has not responded to traditional chemotherapy treatment.

18 Nov 2011

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

Celgene announces interim results of REVLIMID study on CLL

Onyx announces data from three carfilzomib studies on RRMM

Immunomodulators show promise against multiple myeloma

BioInvent announces new BI-505 preclinical data on multiple myeloma

SCRI to present findings of blood cancer trials at 53rd ASH annual meeting

Positive dose-escalation/expansion data from Array BioPharma's ARRY-614 Phase 1 MDS study

Onyx receives FDA Standard Review designation for carfilzomib NDA to treat RRMM

Positive data from Aeterna Zentaris AEZS-131 preclinical study on TNBC

Signal Genetics to launch second generation Myeloma product, MyPRS Plus

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

FDA grants IND for AEZS-130 Phase 2A trial in cancer cachexia

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Biochemists identify structure of hydroxyurea that specifically inhibits proteasome

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Chloroquine-chemotherapy combination holds potential for metastatic breast cancer treatment

Industry Focus: Cell & Gene Therapy eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Industry Focus: Cell & Gene Therapy eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in